# C.E.M. Griffiths

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/c-e-m-griffiths/

## Facts

| Field | Value |
| --- | --- |
| Citations | 70,198 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 129 |
| i10-index | 693 |
| Last Known Institution | King's College London |
| OpenAlex ID | https://openalex.org/A5078821076 |
| ORCID iD | https://orcid.org/0000-0001-5371-4427 |
| Works | 1,258 |

## Researcher papers

- [Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial](https://scholariq.org/papers/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and/)
- [National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study](https://scholariq.org/papers/national-regional-and-worldwide-epidemiology-of-psoriasis-systematic-analysis/)
- [Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity](https://scholariq.org/papers/identification-of-15-new-psoriasis-susceptibility-loci-highlights-the-role-of/)
- [Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial](https://scholariq.org/papers/efficacy-and-safety-of-guselkumab-an-anti-interleukin-23-monoclonal-antibody/)
- [Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis](https://scholariq.org/papers/comparison-of-ustekinumab-and-etanercept-for-moderate-to-severe-psoriasis/)
- [European S3‐Guidelines on the systemic treatment of psoriasis vulgaris](https://scholariq.org/papers/european-s3-guidelines-on-the-systemic-treatment-of-psoriasis-vulgaris/)
- [Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up](https://scholariq.org/papers/long-term-safety-of-ustekinumab-in-patients-with-moderate-to-severe-psoriasis/)
- [Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council](https://scholariq.org/papers/recategorization-of-psoriasis-severity-delphi-consensus-from-the-international/)
- [Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study](https://scholariq.org/papers/factors-associated-with-adverse-covid-19-outcomes-in-patients-with-psoriasis/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Skin Protection and Aging](https://scholariq.org/topics/skin-protection-and-aging/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)

## Researcher university

- [King's College London](https://scholariq.org/institutions/king-s-college-london/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.